Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Article

Immunoglobulin G (IgG) Subclass Distribution and IgG1 Avidity of Antibodies in Human Immunodeficiency Virus-Infected Individuals after Revaccination with Tetanus Toxoid

F. P. Kroon, M. J. D. van Tol, C. M. Jol-van der Zijde, R. van Furth, J. T. van Dissel
F. P. Kroon
Department of Infectious Diseases and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J. D. van Tol
Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. M. Jol-van der Zijde
Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. van Furth
Department of Infectious Diseases and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. T. van Dissel
Department of Infectious Diseases and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CDLI.6.3.352-355.1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In human immunodeficiency virus (HIV)-infected individuals the amount of antibodies formed after vaccination with T-cell-dependent recall antigens such as tetanus toxoid is proportional to the peripheral blood CD4+ T-lymphocyte counts. To investigate whether the immunoglobulin G (IgG) subclass distribution and avidity of the antibodies produced after vaccination are affected as well, we gave 13 HIV-infected adults with low CD4+ T-lymphocyte counts (<200 × 106/liter; group I), 11 HIV-infected adults with intermediate CD4+ T-lymphocyte counts (≥200 × 106/liter; group II), and 5 healthy controls booster immunizations with tetanus toxoid. The prevaccination antibody concentrations against tetanus toxoid were similar in the HIV-infected and healthy adults. After vaccination the total IgG and the IgG1 anti-tetanus toxoid antibody concentrations were significantly lower in group I than in group II and the controls. The avidity of the IgG1 anti-tetanus toxoid antibodies formed by HIV-infected adults was within the range for healthy controls, irrespective of their CD4+T-lymphocyte counts.

In human immunodeficiency virus (HIV)-infected individuals the amount of antibodies formed after vaccination with T-cell-dependent recall antigens, such as tetanus toxoid, is impaired in proportion to the number of CD4+ T cells and to the in vitro proliferative response of T lymphocytes to anti-CD3 monoclonal antibodies (7, 8). Protection against tetanus will depend on the total amount of antibodies, the subclass distribution, and the avidities of the antibodies that are formed. Avidity reflects the combined functional affinities of antibodies formed during a polyclonal humoral immune response and is considered to be a parameter for the efficacy of the antibodies at eliminating or neutralizing the antigen (12). The aim of the present study was to investigate whether, in addition to the concentration of antibodies, the subclass distribution and the avidity of the antibodies formed by HIV-infected individuals after booster vaccination are affected.

(This study was presented in part at the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, Calif., 13 to 16 September 1997.)

MATERIALS AND METHODS

In an earlier study (8) we vaccinated 48 HIV-infected adults and 16 healthy controls with DTPol (National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands), which contains diphtheria toxoid, tetanus toxoid (5 flocculation units), and inactivated poliovirus types 1, 2 and 3. This vaccination was considered to be a booster vaccination since all adult individuals had been vaccinated in the past, most of them during infancy and childhood, according to the national vaccination program for children in The Netherlands, and some of them had received booster vaccinations later in life. The total immunoglobulin G (IgG) anti-tetanus toxoid antibody concentrations before and 30 days after this revaccination were reported previously (8).

For the present study we selected 24 HIV-infected individuals and 5 healthy controls from the population from the study described above. Informed consent was obtained from all individuals. The criteria for inclusion were a prevaccination anti-tetanus toxoid IgG antibody concentration of ≥0.01 arbitrary units/ml (≥0.05 μg/ml) and the ability to mount a humoral response to tetanus toxoid, i.e., a ≥1.25-fold increase in the IgG anti-tetanus toxoid concentration after revaccination (4). Thirteen of 27 HIV-infected individuals with peripheral blood CD4+ T-lymphocyte counts of <200 × 106/liter (group I) and 11 of 21 HIV-infected individuals with ≥200 × 106 CD4+ T lymphocytes/liter (group II) fulfilled the criteria of selection. These individuals did not differ from the nonselected individuals concerning clinical or laboratory parameters, e.g., CD4+ T-lymphocyte counts. Patient characteristics are presented in Table1. In the sera from the selected individuals described above, total IgG, IgG subclasses, and IgA anti-tetanus toxoid antibodies were quantified by an antibody-capture enzyme-linked immunosorbent assay (ELISA) (6). In short, the wells of a 96-well polystyrene microtiter plate were coated with tetanus toxoid, blocked with bovine serum albumin, and incubated with twofold serial dilutions of serum samples and standard sera. Total IgG and IgA anti-tetanus toxoid antibodies were measured by the addition of alkaline phosphatase-conjugated goat anti-human IgG (γ-chain specific) and goat anti-human IgA (α-chain specific), respectively (Tago, Burlingame, Calif.). Antibodies in the IgG subclasses were measured by successive incubation with IgG subclass-specific monoclonal antibodies (anti-IgG1, MH 161-1 [CLB, Amsterdam, The Netherlands]; anti-IgG2, 35-1-27-2 [TNO, Leiden, The Netherlands]; anti-IgG3, NI 86 [Nordic, Tilburg, The Netherlands]; anti-IgG4, NI 315 [Nordic]), followed by incubation with alkaline phosphatase-conjugated rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark). After incubation with substrate ( p -nitrophenylphosphate), the reaction was stopped with 3 M NaOH, and the optical density at 405 nm was recorded with a Titertek Multiscan (Labsystems, Helsinki, Finland). Based on the standard sera containing known amounts of anti-tetanus toxoid antibodies, a reference curve was constructed. Use of this curve allowed the calculation of the amount of anti-tetanus toxoid antibodies of the respective classes or subclasses in the sera of the patients and the controls. The avidity of IgG1 anti-tetanus toxoid was measured by a modified elution ELISA, in which well-chosen dilutions of serum samples were allowed to interact with tetanus toxoid coated on the wells of microtiter plates (9). For each of the serum samples, dilutions containing 50 and 25% of the amount of the anti-tetanus toxoid antibodies which can maximally bind to the coated antigen were chosen. Thereafter, the wells were incubated with a variable molarity (range, 0.5 to 4.5 M) of the chaotropic agent sodium thiocyanate (NaSCN). IgG1 anti-tetanus toxoid antibody levels were then measured as described above. The relative avidity index is defined as the molarity of NaSCN at which 50% of the amount of IgG1 subclass antibodies that are bound to the coated tetanus toxoid in the absence of NaSCN has been eluted from the antigen. Concentrations of antibody and avidity indexes were log transformed to correct for skewness in the distribution. A multiple-comparison procedure was used to determine whether mean values were significantly different between groups (P < 0.05; Bonferroni-adjusted t test).

View this table:
  • View inline
  • View popup
Table 1.

Demographic parameters, CD4+ T-lymphocyte counts, and stage of HIV infection of study participants

RESULTS

Before vaccination, the geometric mean concentrations of total IgG, the IgG subclasses, and IgA antibody against tetanus toxoid were similar in groups I and II and were comparable to those in the healthy controls (Table 2). After vaccination the total IgG anti-tetanus toxoid antibody concentration was significantly lower in group I compared with those in group II and the controls. The IgG anti-tetanus toxoid response after booster vaccination of HIV-infected individuals and healthy controls consisted predominantly (≥75%) of antibodies of the IgG1 subclass (Table 2). Consequently, the production of IgG1 was significantly reduced in group I. The postvaccination geometric mean concentrations of IgG2 and IgG3 anti-tetanus toxoid antibodies were significantly lower in group I than in group II (Table 2). In all groups of patients and controls a significant increase in IgG and IgG1 anti tetanus-toxoid antibodies was induced by vaccination (paired t test of logarithmically normalized values) (Table 2; Fig. 1).

View this table:
  • View inline
  • View popup
Table 2.

Anti-tetanus-toxoid antibody concentrations

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Concentrations of IgG1 anti-tetanus toxoid antibody before and after vaccination with tetanus toxoid. (A) Results for HIV-infected adults with <200 × 106 CD4+T lymphocytes (group I) per liter. (B) Results for HIV-infected adults with ≥200 × 106 CD4+ T lymphocytes (group II) per liter. (C) Results for healthy controls. Horizontal bars depict the geometric mean IgG1 antibody concentrations.

Since the IgG1 anti-tetanus toxoid antibody is quantitatively the major IgG subclass formed after vaccination with tetanus toxoid, the avidity of IgG1 antibodies was investigated. In the HIV-infected individuals with low CD4+ T-lymphocyte counts (group I) and with low IgG1 anti-tetanus toxoid antibody concentrations after vaccination, the mean avidity of the IgG1 anti-tetanus toxoid antibodies was similar to the mean avidity of the IgG1 anti-tetanus toxoid in individuals in group II and in healthy controls (P = 0.2; Bonferroni-adjusted t test) (Fig.2).

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Avidity indices of IgG1 anti-tetanus toxoid antibodies before and after vaccination with tetanus toxoid. (A) Results for HIV-infected adults with <200 × 106 CD4+T lymphocytes (group I) per liter. (B) Results for HIV-infected adults with ≥200 × 106 CD4+ T lymphocytes (group II) per liter. (C) Results for the healthy controls. Horizontal bars depict the mean values of the avidity index for group I, 2.56 before vaccination and 2.7 after vaccination; for group II, 2.76 before vaccination and 2.8 after vaccination; for healthy controls, 3.0 before vaccination and 3.0 after vaccination.

The IgG1 antibodies from three patients with CD4+T-lymphocyte counts of 40 × 106, 40 × 106, and 105 × 106 cells/liter, respectively, demonstrated a significant increase in avidity (Fig. 2A). In all three individuals the IgG1 anti-tetanus toxoid concentration was low before vaccination (1.1, 1.2, and 1.6 μg/ml, respectively) and increased after vaccination only marginally in two individuals (2.0, 2.6, and 9.6 μg/ml, respectively).

DISCUSSION

In earlier studies, we have demonstrated that the formation of IgG anti-tetanus toxoid antibodies after vaccination is impaired in HIV-infected adults with CD4+ T-lymphocyte counts below 300 × 106/liter (7, 8). The results of the present study indicate that the IgG antibodies formed after booster vaccination with tetanus toxoid are predominantly of the IgG1 subclass, both in healthy controls and in HIV-infected individuals. This is compatible with the fact that tetanus toxoid, being a protein antigen, induces a T-cell-dependent immune response which consists mainly of IgG1 in healthy adults (2, 11) as well as in HIV-infected individuals (1). The present study extends our earlier observations and demonstrates that HIV-infected individuals with fewer than 200 CD4+ T lymphocytes exhibit a quantitatively impaired IgG1 anti-tetanus toxoid response. The finding of a normal total IgG anti-tetanus toxoid response, and consequently, a normal IgG1 antibody response, in the HIV-infected individuals with high CD4+ T-lymphocyte counts (group II) confirms the observations of Ballet et al. (1).

Since we found normal tetanus toxoid-specific IgG1 avidity indices even in individuals with low CD4+ T-lymphocyte counts and with low IgG1 anti-tetanus toxoid antibody concentrations, we may conclude that the functional affinity of the formed antibodies is optimal. Janoff et al. (5) have described similar results in HIV-infected individuals by studying the avidity of total IgG anti-tetanus toxoid antibodies.

After repeated vaccination the affinity of antibodies gradually increases. This affinity maturation is a consequence of mutation of the immunoglobulin genes followed by selection of B-cell clones. Such a production of memory B cells, which occurs only in T-cell-dependent antibody responses, confers a long-lasting ability to respond to subsequent encounters with the same antigen (10). A booster vaccination with T-cell-dependent antigens involves activation of memory B cells, which requires less antigen and fewer CD4+T lymphocytes than the activation of unprimed B cells (13). Although HIV-infected individuals with low CD4+T-lymphocyte counts produce less anti-tetanus toxoid antibody after booster vaccination, the memory B lymphocytes, generated during an earlier vaccination, presumably before exposure to HIV, still appear to be effectively triggered and the avidity of the IgG1 anti-tetanus toxoid antibody that is produced is not affected. Interesting in this respect is the observation of the increase in avidity induced by vaccination in three patients with low CD4+ T-lymphocyte counts and low IgG1 anti-tetanus toxoid antibody levels, indicating that somatic hypermutation leading to avidity maturation can still be induced in residual memory B-lymphocyte clones, despite the low numbers of T helper cells.

The results of this study indicate that HIV-infected individuals with low CD4+ T-lymphocyte counts mount a quantitatively decreased but qualitatively normal antibody response to tetanus toxoid revaccination. Therefore, even in this group of HIV-infected individuals, vaccination with a T-cell-dependent recall antigen appears to result in the induction of an antibody response which may be protective.

FOOTNOTES

    • Received 22 July 1998.
    • Returned for modification 28 October 1998.
    • Accepted 19 January 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Ballet J. J.,
    2. Sulcebe G.,
    3. Couderc L. J.,
    4. et al.
    Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin. Exp. Immunol. 68 1987 479 487
    OpenUrlPubMedWeb of Science
  2. 2.↵
    1. Bird P.,
    2. Lowe J.,
    3. Stokes R. P.,
    4. Bird A. G.,
    5. Ling N. R.,
    6. Jefferis R.
    The separation of human serum IgG into subclass fractions by immunoaffinity chromatography and assessment of specific antibody activity. J. Immunol. Methods 71 1984 97 105
    OpenUrlCrossRefPubMed
  3. 3.
    Centers for Disease Control 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Weekly Rep. 41 no. RR-17 1992 1 19
    OpenUrlPubMed
  4. 4.↵
    1. Gerritsen E. J. A.,
    2. van Tol M. J. D.,
    3. van’t Veer M. B.,
    4. et al.
    Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood 84 1994 4374 4382
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Janoff E. N.,
    2. Hardy W. D.,
    3. Smith P. D.,
    4. Wahl S. M.
    Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J. Immunol. 147 1991 2130 2135
    OpenUrlAbstract
  6. 6.↵
    1. Jol-van der Zijde C. M.,
    2. van der Kaaden M.,
    3. Rümke H. C.,
    4. Gerritsen E. J. A.,
    5. Vossen J. M.,
    6. van Tol M. J. D.
    The antibody response against tetanus toxoid: a longitudinal study in healthy infants and adults Progress in immune deficiency III. Chapel H. M., Levinsky R. J., Webster A. D. B. 1991 238 240 Royal Society of Medicine Services Ltd London, United Kingdom
  7. 7.↵
    1. Kroon F. P.,
    2. van Dissel J. T.,
    3. de Jong J. C.,
    4. van Furth R.
    Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 8 1994 469 476
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Kroon F. P.,
    2. van Dissel J. T.,
    3. Labadie J.,
    4. van Loon A. M.,
    5. van Furth R.
    Antibody response to diphtheria, tetanus and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin. Infect Dis. 21 1995 1197 1203
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Pullen G. R.,
    2. Fitzgerald M. G.,
    3. Hosking C. S.
    Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86 1986 83 87
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Rickert R. C.
    Control points and affinity maturation in antibody formation Handbook of experimental immunology 5th ed. Weir D. M. 1997 94.1 4 Blackwell Science, Inc. Malden, Mass
  11. 11.↵
    1. Seppälä I. J. T.,
    2. Routonen N.,
    3. Sarnesto A.,
    4. Mattila P. A.,
    5. Mäkelä O.
    The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay. Eur. J. Immunol. 14 1984 868 875
    OpenUrlPubMedWeb of Science
  12. 12.↵
    1. Steward M. W.
    The biologic significance of antibody affinity. Immunol. Today 2 1981 134 140
    OpenUrlCrossRefWeb of Science
  13. 13.↵
    1. Yefenof E.,
    2. Sanders V. M.,
    3. Uhr J. W.,
    4. Vitetta E. S.
    In vitro activation of murine antigen-specific memory B cells by a T-dependent antigen. J. Immunol. 137 1986 85 90
    OpenUrlAbstract
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Immunoglobulin G (IgG) Subclass Distribution and IgG1 Avidity of Antibodies in Human Immunodeficiency Virus-Infected Individuals after Revaccination with Tetanus Toxoid
F. P. Kroon, M. J. D. van Tol, C. M. Jol-van der Zijde, R. van Furth, J. T. van Dissel
Clinical and Diagnostic Laboratory Immunology May 1999, 6 (3) 352-355; DOI: 10.1128/CDLI.6.3.352-355.1999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Immunoglobulin G (IgG) Subclass Distribution and IgG1 Avidity of Antibodies in Human Immunodeficiency Virus-Infected Individuals after Revaccination with Tetanus Toxoid
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunoglobulin G (IgG) Subclass Distribution and IgG1 Avidity of Antibodies in Human Immunodeficiency Virus-Infected Individuals after Revaccination with Tetanus Toxoid
F. P. Kroon, M. J. D. van Tol, C. M. Jol-van der Zijde, R. van Furth, J. T. van Dissel
Clinical and Diagnostic Laboratory Immunology May 1999, 6 (3) 352-355; DOI: 10.1128/CDLI.6.3.352-355.1999
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X